Introduction
Progressive pulmonary fibrosis (PPF) is characterized by progressive scarring of lung tissue that leads to a decline in lung function and ultimately respiratory failure. Monitoring disease progression and treatment response accurately is essential for improving patient outcomes. Forced vital capacity (FVC) is the commonly used clinical endpoint in trials, yet it has known limitations in sensitivity and an inability to capture nuanced structural changes. To address this, quantitative computed tomography (QCT) imaging is emerging as a powerful tool to detect and predict progression in PPF more sensitively and objectively.
The INBUILD trial, a double-blind, randomized, placebo-controlled study, evaluated the efficacy of nintedanib, an antifibrotic agent, in patients with PPF across various underlying interstitial lung diseases (ILD). A sub-study within INBUILD focused on using QCT methods to refine prognostication and assess treatment effects.
